Abstract:Oxidative stress is believed to play a major role in ischemia-reperfusion injury to the heart. Metallothionein (MT), a potential free radical scavenger, may function in protection against this cardiac injury. Hearts isolated from cardiac MT overexpressing transgenic mice and from the nontransgenic littermates were subjected to 50 min of warm (37 degrees C) zero-flow ischemia followed by 90 min reflow. Compared with the nontransgenic controls, the transgenic hearts with MT concentrations about 10-fold higher than normal, showed significantly improved recovery of contractile force (73% versus 22% at the end of 90 min reperfusion, p < 0.01). Efflux of creatine kinase was reduced by more than 50% and the zone of myocardial infarction as demarcated by triphenyl-tetrazolium at the end of reperfusion was reduced by about 40% in the transgenic hearts compared with the nontransgenic controls. The second parr of this study was to determine the role of MT in the ischemic preconditioning (PC). An open-chest mouse model was used to determine the effect of ischemic PC on MT synthesis in the heart, then the effect of MT induction on ischemic injury. Mouse hearts were processed four cycles of 5 min occlusion and 5 min reperfusion via ligation of left anterior descending coronary artery to produce ischemic PC. At different time points, cardiac MT was measured by a cadmium-hemoglobin affinity assay. Compared to sham-operated mice (6.6 +/- 1.8 mu g/g tissue), MT was significantly (p < 0.01) increased to 15.8 +/- 1.8 and 17.9 +/- 5.0 mu g/g 12 and 24 h, respectively, after ischemic PC. Treatment with cadmium for 24 h increased cardiac MT to the same level as that induced by the ischemic PC and inhibited the subsequent injury induced by ischemia reperfusion. These results indicated that MT functions in cardiac protection against ischemia-reperfusion injury, and it may be an important factor involved in the "second window" of protection induced by ischemic PC.

Activation of HIF-1 by Metallothionein Contributes to Cardiac Protection in the Diabetic Heart.

Hypoxia‐inducible Factor 1α is Critically Involved in Metallothionein Protection Against Diabetic Cardiomyopathy

Metallothionein rescues hypoxia-inducible factor-1 transcriptional activity in cardiomyocytes under diabetic conditions.

Cardiac metallothionein synthesis in streptozotocin-induced diabetic mice, and its protection against diabetes-induced cardiac injury.

Metallothionein Alleviates Cardiac Dysfunction in Streptozotocin-Induced Diabetes: Role of Ca2+ Cycling Proteins, NADPH Oxidase, Poly(adp-Ribose) Polymerase and Myosin Heavy Chain Isozyme

Endothelial Overexpression of Metallothionein Prevents Diabetes Mellitus-Induced Impairment in Ischemia Angiogenesis Via Preservation of HIF-1α/SDF-1/VEGF Signaling in Endothelial Progenitor Cells

Cardiac metallothionein overexpression rescues diabetic cardiomyopathy in Akt2-knockout mice

Stable Overexpression of Human Metallothionein-Iia in A Heart-Derived Cell Line Confers Oxidative Protection

Metallothionein Prevents Diabetes-Induced Deficits in Cardiomyocytes by Inhibiting Reactive Oxygen Species Production.

Metallothionein as an Adaptive Protein Prevents Diabetes and its Toxicity

Diabetes- and angiotensin II-induced cardiac endoplasmic reticulum stress and cell death: metallothionein protection.

Cardiac-Specific Overexpression of HIF-1α Prevents Deterioration of Glycolytic Pathway and Cardiac Remodeling in Streptozotocin-Induced Diabetic Mice

Attenuation by metallothionein of early cardiac cell death via suppression of mitochondrial oxidative stress results in a prevention of diabetic cardiomyopathy.

Metallothionein Prevents Intermittent Hypoxia-Induced Cardiac Endoplasmic Reticulum Stress and Cell Death Likely Via Activation of Akt Signaling Pathway in Mice.

The Adaptive Immune Role Of Metallothioneins In The Pathogenesis Of Diabetic Cardiomyopathy: Good Or Bad

Inactivation of GSK-3beta by metallothionein prevents diabetes-related changes in cardiac energy metabolism, inflammation, nitrosative damage, and remodeling.

Attenuation of AngII‐induced Early Cell Death by MT Results in a Prevention of the Late Development of Cardiomyopathy

Intermittent Hypoxia-Induced Cardiomyopathy and Its Prevention by Nrf2 and Metallothionein.

Modulation Of Cytochrome C Oxidase-Va Is Possibly Involved In Metallothionein Protection From Doxorubicin Cardiotoxicity

Cardiac Protection by Metallothionein Against Ischemia-Reperfusion Injury and Its Possible Relation to Ischemic Preconditioning

Metallothionein Antagonizes Aging-Induced Cardiac Contractile Dysfunction: Role of Ptp1b, Insulin Receptor Tyrosine Phosphorylation and Akt